Type II topoisomerases are ubiquitous enzymes in all branches of life that can alter DNA superhelicity and unlink double-stranded DNA segments during processes such as replication and transcription. In cells, type II topoisomerases are particularly useful for their ability to disentangle newly-replicated sister chromosomes[3]. Teniposide is a topoisomerase II inhibitor. Teniposide (VM-26, 0.15-45 mg/L) inhibits the proliferation of Tca8113 cells in a dose-dependent manner, with an IC50 of 0.35 mg/L. Teniposide (5 mg/L) induces apoptosis of Tca8113 cells. Teniposide (5.0 mg/L) causes cell arrested at G2/M phase in Tca8113 cells[4].Teniposide (0.5 mg/kg, i.p.) significantly increases micronucleated polychromatic erythrocyte (MNPCE) frequencies, which is directly related to bone marrow toxicity as significant suppression of bone marrow is noted. Teniposide (24 mg/kg, i.p.) markedly decreases the frequencies of BrdU-labelled sperm. Teniposide (12, 24 mg/kg, i.p.) also dramatically induces disomic sperm in the germ cell of male mice[5]. Teniposide is active on primary cultured glioma cells from patients, when the level of miR-181b is high in the cells, with an IC50 of 1.3 ± 0.34 μg/mL. Cells treated with teniposide with low MDM2 have decreased viability compared with control cells, and the IC50 decreases from 5.86 ± 0.36 μg/mL to 2.90 ± 0.35 μg/mL upon MDM2 suppression. Teniposide also inhibits the viability of glioma cell with high level of miR-181b, through mediation of MDM2[6].
Teniposide/替尼泊苷 细胞实验
Cell Line
Concentration
Treated Time
Description
References
MDA-MB-231
500 nM
24 hours
To assess the effect of Teniposide on cell viability, results showed minimal impact on cell viability at low concentrations.
Cell Death Dis. 2024 May 8;15(5):322.
Glioblastoma stem-like cells (GSCs)
0.5 µM
24 hours
To evaluate the cytotoxic effect of Teniposide on GSCs under normoxic and hypoxic conditions. Results showed that Teniposide decreased GSC viability under normoxia but no changes were observed under hypoxia, indicating hypoxia enhances chemoresistance of GSCs to Teniposide.
Int J Mol Sci. 2022 Aug 12;23(16):9022.
MDA-MB-231-1833
500 nM
5 days
To evaluate the effect of Teniposide on 3D growth morphology, results showed Teniposide significantly reduced invasive growth morphology.
Cell Death Dis. 2024 May 8;15(5):322.
Teniposide/替尼泊苷 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
BALB/c mice
CT26 tumor model
Intraperitoneal injection
10 mg/kg
Once on day 6 and once on day 7
To evaluate the inhibitory effect of Teniposide on tumor growth and its impact on immune cell infiltration in the tumor microenvironment. Results showed that Teniposide significantly inhibited tumor growth and increased the number and activity of tumor-infiltrating CD8+ T cells.
J Clin Invest. 2019 Aug 13;129(11):4850-4862
C57BL/6J mice
Hepa1-6 liver orthotopic tumor model
Intraperitoneal injection
10 mg/kg
Twice, interval not specified
Evaluate the effect of HBO combined with teniposide treatment on the efficacy of PD-1 antibody. Results showed that HBO significantly enhanced teniposide-induced cGAS-STING-dependent tumor type I interferon and NF-κB signaling, both of which contributed to the activation of dendritic cells and subsequent cytotoxic T cells.
J Immunother Cancer. 2022 Aug;10(8):e004006
Nude mice
Breast cancer lung metastasis model
Tail vein injection
500 nM
Single injection, observed for 21 days
To assess the effect of Teniposide on breast cancer lung metastasis, results showed Teniposide significantly reduced the formation of lung metastatic colonies.
United States, Maryland
... 展开 >>
National Institutes of Health Clinical Center
Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office 888-624-1937 收起 <<
United States, California
... 展开 >>
Rady Children's Hospital and Health Center
Completed
San Diego, California, United States, 92123
United States, Tennessee
St. Jude Children's Research Hospital
Recruiting
Memphis, Tennessee, United States, 38105
Contact: Sima Jeha, MD 866-278-5833 referralinfo@stjude.org
Principal Investigator: Sima Jeha, MD
United States, Texas
Cook Children's Medical Center
Recruiting
Fort Worth, Texas, United States, 76104
Contact: Kenneth M. Heym, MD 682-885-4007
Principal Investigator: Kenneth M. Heym, MD 收起 <<
United States, California
... 展开 >>
Rady Children's Hospital and Health Center
San Diego, California, United States, 92123
United States, Tennessee
St. Jude Children's Research Hospital
Memphis, Tennessee, United States, 38105 收起 <<
China, Henan
... 展开 >> Oncology Department of The First Affiliated Hospital of Zhengzhou University
Recruiting
Zhengzhou, Henan, China, 450052
Contact: Mingzhi Zhang, Pro,Dr 13838565629 mingzhi_zhang@126.com 收起 <<
United States, Illinois
... 展开 >>
Robert H. Lurie Comprehensive Cancer Center, Northwestern University
Chicago, Illinois, United States, 60611-3013 收起 <<
搜索
